Get the Daily Brief
Latest Biotech News
Sino Biological accelerates Nipah research with expanded reagents
Sino Biological announced the expedited availability of research reagents for Nipah virus (NiV) to support vaccine and diagnostic development globally. The company said it is expanding production...
Genyro licenses Caltech’s Sidewinder to write complex DNA at scale
San Diego‑based Genyro licensed Sidewinder, a DNA assembly technology from Caltech, to support large‑scale, high‑accuracy DNA synthesis for programmable biology. Genyro’s CEO Adrian Woolfson...
Origami and Ipsen team up to advance protein degrader program
Origami Therapeutics announced a global collaboration with Ipsen to advance its protein degrader pipeline, focusing on targeted protein degradation modalities. The partnership gives Ipsen rights...
Single‑cell pan‑cancer atlas finds bone‑metastasis clusters and microenvironment cues
A multi‑center single‑cell RNA‑sequencing pan‑cancer study identified expression‑based cancer cell clusters specific to bone metastases and highlighted potentially targetable features of the...
The GLP‑1 carry trade: grey‑market peptides flood demand and pose risk
Investigations and reporting detail an illicit cross‑border supply chain that funnels peptide weight‑loss compounds and research chemicals from Chinese manufacturers to Western consumers,...
EU advisers block Lilly’s Mounjaro for heart failure; back Novo’s semaglutide
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended against approving Eli Lilly’s tirzepatide (Mounjaro) for a heart‑failure indication while...
FDA halts Regenxbio gene trials: cancer case prompts clinical holds
The FDA has placed clinical holds on two Regenxbio gene therapy studies after a patient in one trial developed cancer. Regenxbio is now grappling with regulatory scrutiny that directly affects the...
Phase III flop derails Quince: lead steroid therapy misses endpoints
Quince Therapeutics announced top-line results from its pivotal Neat Phase III trial evaluating dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) in...
Illumina closes SomaLogic deal: proteomics joins sequencing stack
Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash, securing a CLIA/CAP lab in Boulder and technologies tied to SomaScan. The deal...
Beckman, Automata tie up — Danaher backs automation scale-up
Beckman Coulter Life Sciences struck a strategic partnership with Automata to integrate Beckman liquid handling and analytical platforms into Automata’s LINQ AI‑ready automation ecosystem. The...
AstraZeneca doubles down in China: $1.2B CSPC deal and $15B pledge
AstraZeneca announced a China-focused expansion that combines an up‑front $1.2 billion deal with CSPC Pharmaceuticals for obesity and diabetes assets—including a once‑monthly GLP‑1/GIP...
Lilly builds $3.5B obesity plant: retatrutide manufacturing scales up
Eli Lilly unveiled plans for a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, dedicated to producing retatrutide and other obesity injectables and devices. The investment is...
Grail files Galleri with FDA: multi‑cancer blood test seeks premarket approval
Grail submitted its Galleri multi‑cancer early detection blood test for FDA premarket approval, citing performance and safety results from over 25,000 patients in the Pathfinder 2 study and...
Ultragenyx resubmits AAV therapy: Sanfilippo program back in front of FDA
Ultragenyx resubmitted its biologics license application for UX111, an AAV gene therapy targeting Sanfilippo syndrome type A, following an earlier FDA rejection. The resubmission restarts the...
Gut microbes shift asparagine’s role in tumors: immunity versus growth
A study published in Cell Microbe and Host reported that gut bacteria modulate systemic asparagine availability and thereby alter tumor progression and anti‑tumor immunity. Researchers showed...
FDA recommends MRD for myeloma accelerated approvals: draft raises standards
The FDA issued draft guidance advising sponsors to use minimal residual disease (MRD) negativity as an intermediate endpoint for accelerated approval of multiple myeloma therapies. The agency...
AstraZeneca doubles down on weight-loss and China bets: $1.2B upfront, $15B horizon
AstraZeneca executed a major deal to expand its metabolic and obesity pipeline and outlined large-scale China investments. The company struck a partnership with CSPC that includes an $1.2 billion...
Illumina finalizes SomaLogic buy: proteomics joins sequencing stack
Illumina closed its acquisition of SomaLogic and related assets in a cash deal that expands the company's move into proteomics and multiomics. The transaction transfers SomaLogic technologies and...
Beckman Coulter ties instruments to Automata’s AI-ready automation
Beckman Coulter Life Sciences and Automata announced a strategic partnership to embed Beckman’s liquid‑handling and analysis instruments into Automata’s LINQ automation ecosystem and support...
Quince’s Phase III failure devastates A-T program and market value
Quince Therapeutics announced top-line Phase III results from the Neat trial for its once‑monthly dexamethasone-in-erythrocyte program (eDSP) in ataxia‑telangiectasia (A‑T) that missed the primary...